Justin Andrew Caravella

US Patent:

20080221176, Sep 11, 2008

Filed:

Aug 23, 2006

Appl. No.:

12/064502

Inventors:

John Loren Collins - Durham NC, US
Eugene Lee Stewart - Durham NC, US
William Zuercher - Durham NC, US
Esther Chao - Durham NC, US
Robert Wiethe - Durham NC, US
Justin Caravella - Durham NC, US

International Classification:

A61K 31/4402
C07C 211/29
C07D 213/36
A61P 3/10
A61P 9/10
A61K 31/4409
A61K 31/138

US Classification:

514357, 564442, 514655, 546334

Abstract:

This invention relates to compounds that are modulators of the liver X receptors (LXRs), and also to the methods for the making and use of such compounds.

US Patent:

20100120775, May 13, 2010

Filed:

Oct 23, 2007

Appl. No.:

12/446594

Inventors:

David Norman Deaton - Durham NC, US
Justin Caravella - Durham NC, US
Robert Blount McFadyen - Durham NC, US
Frank Navas, III - Durham NC, US
Paul Kenneth Spearing - Durham NC, US

Assignee:

SMITHKLINE BEECHAM CORPORATION - Philadelphia PA

International Classification:

A61K 31/498
C07D 215/20
A61K 31/47
C07D 413/02
A61K 31/517
C07D 241/36
A61P 3/04
A61P 3/10
A61P 1/16

US Classification:

514249, 546170, 514314, 544284, 5142662, 544355

Abstract:

The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

US Patent:

20120003235, Jan 5, 2012

Filed:

Dec 31, 2009

Appl. No.:

13/141297

Inventors:

Ann M. Ranger - Northborough MA, US
Ellen Garber - Cambridge MA, US
Justin A. Caravella - Cambridge MA, US
Alexey A. Lugovskoy - Woburn MA, US
Joseph Arndt - Peabody MA, US
Frederick R. Taylor - Milton MA, US
Giovanna Antognetti - Foxboro MA, US
Eric Day - Cambridge MA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

A61K 39/395
C12N 15/13
C12N 15/63
C12N 1/21
C12N 1/19
C12N 5/10
C12P 21/00
A61P 29/00
A61P 19/02
A61P 25/00
A61P 17/06
A61P 3/10
A61P 9/10
A61P 35/00
C07K 16/24

US Classification:

4241581, 5303892, 5303873, 536 2353, 4353201, 4352523, 43525233, 43525231, 4352542, 43525421, 43525423, 435335, 435 696

Abstract:

The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LTβR signaling are also provided.

US Patent:

20140079701, Mar 20, 2014

Filed:

Dec 22, 2011

Appl. No.:

13/996918

Inventors:

Brian Robert Miller - San Diego CA, US
Scott Glaser - San Diego CA, US
Justin Caravella - Cambridge MA, US
Susan Foley - Milford MA, US
Tigran Dikran Alvazian - San Diego CA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

C07K 7/08
C07K 16/24

US Classification:

4241351, 530328, 530322, 530326, 5303873, 530351, 435188, 514 216, 536 231, 435328, 4241331, 536 234, 4353201, 435 697, 435 696, 4352523, 4352542, 435419, 43525233, 43525231, 43525421

Abstract:

The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.

US Patent:

20140079716, Mar 20, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/830500

Inventors:

BIOGEN IDEC MA INC. - , US
Ellen GARBER - Cambridge MA, US
Justin A. CARAVELLA - Cambridge MA, US
Alexey A. LUGOVSKOY - Woburn MA, US
Joseph ARNDT - Peabody MA, US
Frederick R. TAYLOR - Milton MA, US
Giovanna ANTOGNETTI - Foxboro MA, US
Eric DAY - Cambridge MA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

C07K 14/525

US Classification:

4241581, 5303892, 536 2353, 4353201, 4352523, 435 696, 43525233, 43525231, 4352542, 43525421, 43525423, 435335

Abstract:

The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LTβR signaling are also provided.

US Patent:

7960552, Jun 14, 2011

Filed:

Oct 23, 2007

Appl. No.:

11/876906

Inventors:

Justin Caravella - Durham NC, US
David Norman Deaton - Durham NC, US
Robert Blount McFadyen - Durham NC, US
Frank Navas, III - Durham NC, US
Paul Kenneth Spearing - Durham NC, US

Assignee:

GlaxoSmithKline LLC - Philadelphia PA

International Classification:

C07D 401/00

US Classification:

546167

Abstract:

The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

US Patent:

20220281869, Sep 8, 2022

Filed:

Sep 30, 2021

Appl. No.:

17/490482

Inventors:

- Watertown MA, US
Stephanos Ioannidis - Natick MA, US
Bruce Follows - Littleton MA, US
Gary Gustafson - Ridgefield CT, US
Minghua Wang - Acton MA, US
Justin Andrew Caravella - Cambridge MA, US
Zhongguo Wang - Lexington MA, US
Edward L. Fritzen - Niantic CT, US
Jian Lin - Acton MA, US

International Classification:

C07D 473/00
A61K 31/522

Abstract:

The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula:where R, R, R, R, R, R, X, X, X, X, and n are described herein.

US Patent:

20230125739, Apr 27, 2023

Filed:

Nov 9, 2022

Appl. No.:

17/984069

Inventors:

- Watertown MA, US
Anna Ericsson - Shrewsbury MA, US
Ann-Marie Campbell - Monroe CT, US
Gary Gustafson - Ridgefield CT, US
Zhongguo Wang - Lexington MA, US
R. Bruce Diebold - Waltham MA, US
Susan Ashwell - Carlisle MA, US
Justin Andrew Caravella - Cambridge MA, US
Wei Lu - Newton MA, US

Assignee:

FORMA Therapeutics, Inc. - Watertown MA

International Classification:

C07D 401/12
C07D 401/14
C07D 471/04
A61P 35/00

Abstract:

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, U, W, W, W, R-R, and Rare described herein.